New immunotherapeutic paradigms for castration-resistant prostate cancer.
作者信息
Galluzzi Lorenzo
机构信息
Gustave Roussy; Villejuif, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité; Paris, France; Equipe 11 labelisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers; Paris, France.
出版信息
Oncoimmunology. 2013 Aug 7;2(8):e26084. doi: 10.4161/onci.26084. eCollection 2013 Aug.
Abstract
摘要
相似文献
1
New immunotherapeutic paradigms for castration-resistant prostate cancer.去势抵抗性前列腺癌的新免疫治疗模式
Oncoimmunology. 2013 Aug 7;2(8):e26084. doi: 10.4161/onci.26084. eCollection 2013 Aug.
2
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.注射用前列腺酸性磷酸酶疫苗（Provenge®）治疗去势抵抗性前列腺癌。
BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16.
3
A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer.镭-223（Xofigo）对转移性去势抵抗性前列腺癌患者全血细胞减少症影响的单中心回顾性分析
Cureus. 2020 Jan 28;12(1):e6806. doi: 10.7759/cureus.6806.
4
Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.化疗前阶段转移性去势抵抗性前列腺癌的管理：新靶向药物时代不断变化的方法
Drugs. 2016 Mar;76(4):421-30. doi: 10.1007/s40265-015-0530-7.
5
New agents for the management of castration-resistant prostate cancer.用于治疗去势抵抗性前列腺癌的新药物。
Ann Pharmacother. 2012 Nov;46(11):1518-28. doi: 10.1345/aph.1R169. Epub 2012 Nov 7.
6
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.免疫疗法在去势抵抗性前列腺癌中的应用：将 sipuleucel-T 纳入我们当前的治疗模式。
Oncology (Williston Park). 2011 Mar;25(3):242-9.
7
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.西妥昔单抗 - T 在晚期前列腺癌患者治疗中的作用是什么？证据更新
Ther Adv Urol. 2016 Aug;8(4):272-278. doi: 10.1177/1756287216645314. Epub 2016 May 2.
8
Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.转移性去势抵抗性前列腺癌的治疗导航：护理视角
Clin J Oncol Nurs. 2015 Dec;19(6):723-32. doi: 10.1188/15.CJON.723-732.
9
Novel agents for castration-resistant prostate cancer: Early experience and beyond.去势抵抗性前列腺癌的新型药物：早期经验及其他
Int J Urol. 2016 Feb;23(2):114-21. doi: 10.1111/iju.12907. Epub 2015 Aug 27.
10
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.用于去势抵抗性前列腺癌的西普拉塞-T（普罗文奇®）
BJU Int. 2012 Jul;110(2 Pt 2):E105. doi: 10.1111/j.1464-410X.2011.10820.x. Epub 2011 Dec 16.
引用本文的文献
1
Trial Watch: Proteasomal inhibitors for anticancer therapy.试验观察：用于抗癌治疗的蛋白酶体抑制剂
Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. eCollection 2015 Apr-Jun.
2
Trial Watch-Immunostimulation with cytokines in cancer therapy.试验观察——癌症治疗中细胞因子免疫刺激疗法
Oncoimmunology. 2015 Dec 8;5(2):e1115942. doi: 10.1080/2162402X.2015.1115942. eCollection 2016 Feb.
3
Trial watch: Naked and vectored DNA-based anticancer vaccines.试验观察：裸 DNA 与载体 DNA 抗癌疫苗。
Oncoimmunology. 2015 Apr 2;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.
4
Trial watch: Dendritic cell-based anticancer therapy.试验观察：基于树突状细胞的抗癌疗法。
Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov.
5
Classification of current anticancer immunotherapies.当前抗癌免疫疗法的分类。
Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998.
6
Trial Watch:: Oncolytic viruses for cancer therapy.试验观察：用于癌症治疗的溶瘤病毒
Oncoimmunology. 2014 Jun 1;3:e28694. doi: 10.4161/onci.28694. eCollection 2014.
7
Trial Watch: DNA vaccines for cancer therapy.试验观察：用于癌症治疗的 DNA 疫苗。
Oncoimmunology. 2014 Jan 1;3(1):e28185. doi: 10.4161/onci.28185. Epub 2014 Apr 1.
8
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.试验观察：肿瘤靶向单克隆抗体在癌症治疗中的应用。
Oncoimmunology. 2014 Jan 1;3(1):e27048. doi: 10.4161/onci.27048.
9
Trial Watch: Peptide vaccines in cancer therapy.试验观察：癌症治疗中的肽疫苗。
Oncoimmunology. 2013 Dec 1;2(12):e26621. doi: 10.4161/onci.26621. Epub 2013 Nov 4.
本文引用的文献
1
Trial Watch: Anticancer radioimmunotherapy.试验观察：抗癌放射性免疫疗法。
Oncoimmunology. 2013 Sep 1;2(9):e25595. doi: 10.4161/onci.25595. Epub 2013 Jul 3.
2
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.试验观察：用于抗癌免疫治疗的过继性细胞转移
Oncoimmunology. 2013 May 1;2(5):e24238. doi: 10.4161/onci.24238.
3
An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells.一种消除四倍体细胞的抗癌治疗引发的免疫监视系统。
Oncoimmunology. 2013 Jan 1;2(1):e22409. doi: 10.4161/onci.22409.
4
Trial watch: Monoclonal antibodies in cancer therapy.试验观察：癌症治疗中的单克隆抗体
Oncoimmunology. 2013 Jan 1;2(1):e22789. doi: 10.4161/onci.22789.
5
Trial watch: Dendritic cell-based interventions for cancer therapy.试验观察：基于树突状细胞的癌症治疗干预措施
Oncoimmunology. 2012 Oct 1;1(7):1111-1134. doi: 10.4161/onci.21494.
6
Immunogenic cell death in cancer therapy.肿瘤免疫治疗中的免疫原性细胞死亡
Annu Rev Immunol. 2013;31:51-72. doi: 10.1146/annurev-immunol-032712-100008. Epub 2012 Nov 12.
7
Retraction. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.撤回声明。在R462Q RNASEL变体纯合患者的前列腺肿瘤中鉴定出一种新型γ逆转录病毒。
PLoS Pathog. 2012 Sep;8(9). doi: 10.1371/annotation/7e2efc01-2e9b-4e9b-aef0-87ab0e4e4732. Epub 2012 Sep 18.
8
An immunosurveillance mechanism controls cancer cell ploidy.免疫监视机制控制癌细胞的倍性。
Science. 2012 Sep 28;337(6102):1678-84. doi: 10.1126/science.1224922.
9
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.镭-223 氯化物治疗伴有骨转移和去势抵抗性前列腺癌患者的随机、双盲、剂量发现、多中心、Ⅱ期研究。
Eur Urol. 2013 Feb;63(2):189-97. doi: 10.1016/j.eururo.2012.09.008. Epub 2012 Sep 13.
10
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.英国国家卫生与临床优化研究所（NICE）关于卡巴他赛用于先前接受过含多西他赛方案治疗的激素难治性转移性前列腺癌的指南。
Lancet Oncol. 2012 Jun;13(6):573-4. doi: 10.1016/s1470-2045(12)70220-6.
Zotero 插件